Carl Zeiss Meditec Enhances Clinical Value by Offering Solutions for Cataract and Refractive Surgery

SAN DIEGO, CA -- (MARKET WIRE) -- April 30, 2007 -- ASCRS Booth # 2641 Hall D -- Carl Zeiss Meditec, Inc. will demonstrate its newest technologies and gold-standard products here at the American Society of Cataract and Refractive Surgery (ASCRS) meeting in San Diego, April 28 - May 1, 2007. The company's platforms and technological advancements address a broad spectrum of applications designed to improve workflow and enhance patient management.

"Our newest initiatives coupled with recent advances to existing product platforms reflect our focused commitment to the continuous development and enhancement of technical capabilities," said Jim Taylor, president and chief executive officer of Carl Zeiss Meditec, Inc. "Our platforms are designed not only to offer solutions for today's urgent clinical demands, but also with a vision for future needs."

Product Platforms to be Highlighted

Offering refractive laser systems for the effective and patient-friendly correction of vision defects, the company will demonstrate its MEL 80™ excimer system and the VISUMAX™ femtosecond laser system, which recently received U.S. Food & Drug Administration (FDA) clearance. Clinical trials for the MEL 80 showed that 93 percent of patients were corrected at three months to 20/20 or better visual acuity, and 41 percent were corrected to 20/12.5 or better at six months. Additionally, 85 percent of the patients achieved within one-half of a diopter of the intended correction at the three month post-operative follow-up. The combination of both platform lasers, including the pivoting patient bed and integrated data management system, will enable physicians to complete a full refractive procedure in one location without the need to move the patient, or perform redundant data entries.

Joining the market-leading Stratus OCT, the company will demonstrate its latest advancement in spectral domain OCT with the Cirrus™ HD-OCT platform. This high-end instrument is ideal for the most demanding retinal cases because it offers proprietary high definition technology for superior imaging and visualization of the retinal tissue. This high definition spectral domain technology has faster scanning capabilities, capturing more data and revealing greater detail of retinal tissue and pathology. Additionally, the Cirrus system's high precision measurements facilitate structural evaluation and monitoring.

The company will also showcase the newest applications for the Stratus OCT™ platform, which is recognized as the standard-of-care instrument supporting comprehensive eye-care professionals and retinal specialists worldwide. The in-vivo cross sectional images and quantitative analysis of the retina help to facilitate a more complete assessment of cataract patients pre- and post-operatively, as well as patients with glaucoma and retinal disease for enhanced patient management.

Further evidence of CZM's commitment to OCT technology includes the Visante OCT -- the first stand-alone, high resolution OCT system for the anterior segment of the eye, including the cornea, iris, angle and the lens. The company will introduce new refractive tools for surgical planning along with its latest iridocorneal tools for glaucoma patient assessment.

Carl Zeiss Meditec has been leading the development of progression analysis for more than 20 years, offering significant clinical benefits that ultimately increase the potential for correct diagnoses. The new Guided Progression Analysis™ (GPA) tools for the GDx Scanning Laser Polarimeter and Stratus OCT, coupled with the enhanced tools for the Humphrey® Field Analyzer, will help doctors to make accurate, individual treatment decisions.

The company's suite of platforms also supports today's connectivity needs with a pathway for the electronic workflow demands of the future. The new VISUPAC Star Storage and Review software is the single platform that organizes all Carl Zeiss Meditec images and print data into a patient-centric database. With improved access to current and past data, patient consultation is enhanced and workflow is considerably improved on a daily basis. In addition, the VISUPAC Star software supports EMR integration; therefore standardized interface protocols are available to all EMR vendors.

To see a demonstration of these products and learn more about the company, please stop by the Carl Zeiss Meditec booth at ASCRS (Booth #2641 Hall D) or visit www.meditec.zeiss.com/usa.

About Carl Zeiss Meditec

Carl Zeiss Meditec AG (ISIN: DE 0005313704) is one of the world's leading medical technology companies. This market position is based on over 160 years of experience in optical innovation. The company has two primary areas of activity. In the field of ophthalmology, Carl Zeiss Meditec offers integrated solutions for treating the four main eye diseases: vision defects (refraction), cataracts, glaucoma and retinal disorders. Product innovations range from basic systems such as slit lamps and fundus cameras to standard setting diagnostic systems such as the Humphrey® Field Analyzer, the Stratus OCT™ and the IOLMaster®, through to the surgical microscopes and innovative treatment systems in refractive laser surgery.

In the field of neuro and ENT surgery, Carl Zeiss Meditec is the world's leading provider of surgical microscopes and microsurgical visualization solutions for a very broad range of applications, such as tumour and vascular surgery in the head region and/or spinal surgery. The most recent example of our innovative performance in the area of microsurgery is the OPMI Pentero® visualization system, which allows efficient and ergonomic patient treatment.

Carl Zeiss Meditec's medical technology portfolio is rounded off by visualization systems for doctors in private practice and promising future technologies such as intraoperative radiation therapy, which allows the targeted treatment of breast cancer and brain cancer directly during surgery.

Carl Zeiss Meditec AG is based in Jena, Germany, with subsidiaries in Germany (Carl Zeiss Meditec Surgical GmbH and Carl Zeiss Meditec Vertriebsgesellschaf mbH), the USA (Carl Zeiss Meditec, Inc., Dublin, California), in Japan (Carl Zeiss Meditec Co., Ltd., Tokyo), Spain (Carl Zeiss Meditec Iberia S.A., Madrid) and France (Ioltech SAS, La Rochelle, and Carl Zeiss Meditec France SAS, Le Pecq).

Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss, one of the world's leading international groups engaged in the optical and opto-electronics industry. For more information, visit www.meditec.zeiss.com/usa.

Contact Information: Media Contact: Amy Cook 925.552.7893 Email Contact